A Nevada district judge last week invalidated patents for Amarin’s Vascepa, a fish-oil based cholesterol drug that was poised as a blockbuster. Vascepa will now be open to generic competition, though none are currently approved by the FDA. The drugmaker said it will appeal the decision. Vascepa currently holds preferred status for 24% of all covered lives in the United States.
SOURCE: MMIT Analytics, as of 4/1/20